INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7601, 29582, 'Metoclopramide', 'Water-Electrolyte Imbalance', 'Metoclopramide produces a transient increase in plasma aldosterone and may cause fluid retention and volume overload in susceptible patients.  Therapy with metoclopramide should be administered cautiously in patients with or at risk for fluid overload (e.g., cirrhosis, congestive heart failure).  If these side effects occur at any time during metoclopramide therapy, the drug should be discontinued.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7602, 29583, 'Metoclopramide', 'Water-Electrolyte Imbalance', 'Metoclopramide produces a transient increase in plasma aldosterone and may cause fluid retention and volume overload in susceptible patients.  Therapy with metoclopramide should be administered cautiously in patients with or at risk for fluid overload (e.g., cirrhosis, congestive heart failure).  If these side effects occur at any time during metoclopramide therapy, the drug should be discontinued.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7603, 516, 'Metoclopramide', 'Hypertension', 'In a study involving patients with essential hypertension, intravenously administered metoclopramide was shown to induce the release of catecholamines.  Therapy with metoclopramide should be administered cautiously in patients with hypertension because of potential increases in blood pressure.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7604, 2797, 'Metoclopramide', 'Hypertension', 'In a study involving patients with essential hypertension, intravenously administered metoclopramide was shown to induce the release of catecholamines.  Therapy with metoclopramide should be administered cautiously in patients with hypertension because of potential increases in blood pressure.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7605, 7824, 'Metoclopramide', 'Hypertension', 'In a study involving patients with essential hypertension, intravenously administered metoclopramide was shown to induce the release of catecholamines.  Therapy with metoclopramide should be administered cautiously in patients with hypertension because of potential increases in blood pressure.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7606, 7825, 'Metoclopramide', 'Hypertension', 'In a study involving patients with essential hypertension, intravenously administered metoclopramide was shown to induce the release of catecholamines.  Therapy with metoclopramide should be administered cautiously in patients with hypertension because of potential increases in blood pressure.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7607, 7826, 'Metoclopramide', 'Hypertension', 'In a study involving patients with essential hypertension, intravenously administered metoclopramide was shown to induce the release of catecholamines.  Therapy with metoclopramide should be administered cautiously in patients with hypertension because of potential increases in blood pressure.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7608, 7827, 'Metoclopramide', 'Hypertension', 'In a study involving patients with essential hypertension, intravenously administered metoclopramide was shown to induce the release of catecholamines.  Therapy with metoclopramide should be administered cautiously in patients with hypertension because of potential increases in blood pressure.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7609, 7828, 'Metoclopramide', 'Hypertension', 'In a study involving patients with essential hypertension, intravenously administered metoclopramide was shown to induce the release of catecholamines.  Therapy with metoclopramide should be administered cautiously in patients with hypertension because of potential increases in blood pressure.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7610, 8097, 'Metoclopramide', 'Hypertension', 'In a study involving patients with essential hypertension, intravenously administered metoclopramide was shown to induce the release of catecholamines.  Therapy with metoclopramide should be administered cautiously in patients with hypertension because of potential increases in blood pressure.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7611, 25000, 'Metoclopramide', 'Hypertension', 'In a study involving patients with essential hypertension, intravenously administered metoclopramide was shown to induce the release of catecholamines.  Therapy with metoclopramide should be administered cautiously in patients with hypertension because of potential increases in blood pressure.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7612, 25001, 'Metoclopramide', 'Hypertension', 'In a study involving patients with essential hypertension, intravenously administered metoclopramide was shown to induce the release of catecholamines.  Therapy with metoclopramide should be administered cautiously in patients with hypertension because of potential increases in blood pressure.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7613, 25002, 'Metoclopramide', 'Hypertension', 'In a study involving patients with essential hypertension, intravenously administered metoclopramide was shown to induce the release of catecholamines.  Therapy with metoclopramide should be administered cautiously in patients with hypertension because of potential increases in blood pressure.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7614, 25257, 'Metoclopramide', 'Hypertension', 'In a study involving patients with essential hypertension, intravenously administered metoclopramide was shown to induce the release of catecholamines.  Therapy with metoclopramide should be administered cautiously in patients with hypertension because of potential increases in blood pressure.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7615, 25259, 'Metoclopramide', 'Hypertension', 'In a study involving patients with essential hypertension, intravenously administered metoclopramide was shown to induce the release of catecholamines.  Therapy with metoclopramide should be administered cautiously in patients with hypertension because of potential increases in blood pressure.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7616, 25261, 'Metoclopramide', 'Hypertension', 'In a study involving patients with essential hypertension, intravenously administered metoclopramide was shown to induce the release of catecholamines.  Therapy with metoclopramide should be administered cautiously in patients with hypertension because of potential increases in blood pressure.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7617, 27683, 'Metoclopramide', 'Hypertension', 'In a study involving patients with essential hypertension, intravenously administered metoclopramide was shown to induce the release of catecholamines.  Therapy with metoclopramide should be administered cautiously in patients with hypertension because of potential increases in blood pressure.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7618, 29582, 'Metoclopramide', 'Hypertension', 'In a study involving patients with essential hypertension, intravenously administered metoclopramide was shown to induce the release of catecholamines.  Therapy with metoclopramide should be administered cautiously in patients with hypertension because of potential increases in blood pressure.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7619, 29583, 'Metoclopramide', 'Hypertension', 'In a study involving patients with essential hypertension, intravenously administered metoclopramide was shown to induce the release of catecholamines.  Therapy with metoclopramide should be administered cautiously in patients with hypertension because of potential increases in blood pressure.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7620, 516, 'Metoclopramide', 'Parkinsonian Disorders', 'Metoclopramide has antidopaminergic effects and may cause parkinsonian-like symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually within the first six months following initiation of therapy but occasionally after longer periods.  Symptoms generally subside within 2 to 3 months after drug discontinuation.  Therapy with metoclopramide should be administered cautiously, if at all, in patients with Parkinson''s disease or parkinsonian symptoms.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7621, 2797, 'Metoclopramide', 'Parkinsonian Disorders', 'Metoclopramide has antidopaminergic effects and may cause parkinsonian-like symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually within the first six months following initiation of therapy but occasionally after longer periods.  Symptoms generally subside within 2 to 3 months after drug discontinuation.  Therapy with metoclopramide should be administered cautiously, if at all, in patients with Parkinson''s disease or parkinsonian symptoms.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7622, 7824, 'Metoclopramide', 'Parkinsonian Disorders', 'Metoclopramide has antidopaminergic effects and may cause parkinsonian-like symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually within the first six months following initiation of therapy but occasionally after longer periods.  Symptoms generally subside within 2 to 3 months after drug discontinuation.  Therapy with metoclopramide should be administered cautiously, if at all, in patients with Parkinson''s disease or parkinsonian symptoms.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7623, 7825, 'Metoclopramide', 'Parkinsonian Disorders', 'Metoclopramide has antidopaminergic effects and may cause parkinsonian-like symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually within the first six months following initiation of therapy but occasionally after longer periods.  Symptoms generally subside within 2 to 3 months after drug discontinuation.  Therapy with metoclopramide should be administered cautiously, if at all, in patients with Parkinson''s disease or parkinsonian symptoms.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7624, 7826, 'Metoclopramide', 'Parkinsonian Disorders', 'Metoclopramide has antidopaminergic effects and may cause parkinsonian-like symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually within the first six months following initiation of therapy but occasionally after longer periods.  Symptoms generally subside within 2 to 3 months after drug discontinuation.  Therapy with metoclopramide should be administered cautiously, if at all, in patients with Parkinson''s disease or parkinsonian symptoms.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7625, 7827, 'Metoclopramide', 'Parkinsonian Disorders', 'Metoclopramide has antidopaminergic effects and may cause parkinsonian-like symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually within the first six months following initiation of therapy but occasionally after longer periods.  Symptoms generally subside within 2 to 3 months after drug discontinuation.  Therapy with metoclopramide should be administered cautiously, if at all, in patients with Parkinson''s disease or parkinsonian symptoms.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7626, 7828, 'Metoclopramide', 'Parkinsonian Disorders', 'Metoclopramide has antidopaminergic effects and may cause parkinsonian-like symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually within the first six months following initiation of therapy but occasionally after longer periods.  Symptoms generally subside within 2 to 3 months after drug discontinuation.  Therapy with metoclopramide should be administered cautiously, if at all, in patients with Parkinson''s disease or parkinsonian symptoms.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7627, 8097, 'Metoclopramide', 'Parkinsonian Disorders', 'Metoclopramide has antidopaminergic effects and may cause parkinsonian-like symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually within the first six months following initiation of therapy but occasionally after longer periods.  Symptoms generally subside within 2 to 3 months after drug discontinuation.  Therapy with metoclopramide should be administered cautiously, if at all, in patients with Parkinson''s disease or parkinsonian symptoms.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7628, 25000, 'Metoclopramide', 'Parkinsonian Disorders', 'Metoclopramide has antidopaminergic effects and may cause parkinsonian-like symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually within the first six months following initiation of therapy but occasionally after longer periods.  Symptoms generally subside within 2 to 3 months after drug discontinuation.  Therapy with metoclopramide should be administered cautiously, if at all, in patients with Parkinson''s disease or parkinsonian symptoms.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7629, 25001, 'Metoclopramide', 'Parkinsonian Disorders', 'Metoclopramide has antidopaminergic effects and may cause parkinsonian-like symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually within the first six months following initiation of therapy but occasionally after longer periods.  Symptoms generally subside within 2 to 3 months after drug discontinuation.  Therapy with metoclopramide should be administered cautiously, if at all, in patients with Parkinson''s disease or parkinsonian symptoms.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7630, 25002, 'Metoclopramide', 'Parkinsonian Disorders', 'Metoclopramide has antidopaminergic effects and may cause parkinsonian-like symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually within the first six months following initiation of therapy but occasionally after longer periods.  Symptoms generally subside within 2 to 3 months after drug discontinuation.  Therapy with metoclopramide should be administered cautiously, if at all, in patients with Parkinson''s disease or parkinsonian symptoms.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7631, 25257, 'Metoclopramide', 'Parkinsonian Disorders', 'Metoclopramide has antidopaminergic effects and may cause parkinsonian-like symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually within the first six months following initiation of therapy but occasionally after longer periods.  Symptoms generally subside within 2 to 3 months after drug discontinuation.  Therapy with metoclopramide should be administered cautiously, if at all, in patients with Parkinson''s disease or parkinsonian symptoms.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7632, 25259, 'Metoclopramide', 'Parkinsonian Disorders', 'Metoclopramide has antidopaminergic effects and may cause parkinsonian-like symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually within the first six months following initiation of therapy but occasionally after longer periods.  Symptoms generally subside within 2 to 3 months after drug discontinuation.  Therapy with metoclopramide should be administered cautiously, if at all, in patients with Parkinson''s disease or parkinsonian symptoms.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7633, 25261, 'Metoclopramide', 'Parkinsonian Disorders', 'Metoclopramide has antidopaminergic effects and may cause parkinsonian-like symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually within the first six months following initiation of therapy but occasionally after longer periods.  Symptoms generally subside within 2 to 3 months after drug discontinuation.  Therapy with metoclopramide should be administered cautiously, if at all, in patients with Parkinson''s disease or parkinsonian symptoms.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7634, 27683, 'Metoclopramide', 'Parkinsonian Disorders', 'Metoclopramide has antidopaminergic effects and may cause parkinsonian-like symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually within the first six months following initiation of therapy but occasionally after longer periods.  Symptoms generally subside within 2 to 3 months after drug discontinuation.  Therapy with metoclopramide should be administered cautiously, if at all, in patients with Parkinson''s disease or parkinsonian symptoms.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7635, 29582, 'Metoclopramide', 'Parkinsonian Disorders', 'Metoclopramide has antidopaminergic effects and may cause parkinsonian-like symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually within the first six months following initiation of therapy but occasionally after longer periods.  Symptoms generally subside within 2 to 3 months after drug discontinuation.  Therapy with metoclopramide should be administered cautiously, if at all, in patients with Parkinson''s disease or parkinsonian symptoms.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7636, 29583, 'Metoclopramide', 'Parkinsonian Disorders', 'Metoclopramide has antidopaminergic effects and may cause parkinsonian-like symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually within the first six months following initiation of therapy but occasionally after longer periods.  Symptoms generally subside within 2 to 3 months after drug discontinuation.  Therapy with metoclopramide should be administered cautiously, if at all, in patients with Parkinson''s disease or parkinsonian symptoms.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7637, 516, 'Metoclopramide', 'Kidney Diseases', 'Renal function affects the clearance of metoclopramide.  In patients with varying degrees of renal impairment, a reduction in creatinine clearance was correlated with a reduction in plasma clearance, renal clearance, and non-renal clearance, and increase in elimination half-life of metoclopramide.  Therapy with metoclopramide should be administered cautiously in patients with impaired renal function.  A dosage reduction may be appropriate to avoid drug accumulation.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7638, 2797, 'Metoclopramide', 'Kidney Diseases', 'Renal function affects the clearance of metoclopramide.  In patients with varying degrees of renal impairment, a reduction in creatinine clearance was correlated with a reduction in plasma clearance, renal clearance, and non-renal clearance, and increase in elimination half-life of metoclopramide.  Therapy with metoclopramide should be administered cautiously in patients with impaired renal function.  A dosage reduction may be appropriate to avoid drug accumulation.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7639, 7824, 'Metoclopramide', 'Kidney Diseases', 'Renal function affects the clearance of metoclopramide.  In patients with varying degrees of renal impairment, a reduction in creatinine clearance was correlated with a reduction in plasma clearance, renal clearance, and non-renal clearance, and increase in elimination half-life of metoclopramide.  Therapy with metoclopramide should be administered cautiously in patients with impaired renal function.  A dosage reduction may be appropriate to avoid drug accumulation.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7640, 7825, 'Metoclopramide', 'Kidney Diseases', 'Renal function affects the clearance of metoclopramide.  In patients with varying degrees of renal impairment, a reduction in creatinine clearance was correlated with a reduction in plasma clearance, renal clearance, and non-renal clearance, and increase in elimination half-life of metoclopramide.  Therapy with metoclopramide should be administered cautiously in patients with impaired renal function.  A dosage reduction may be appropriate to avoid drug accumulation.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7641, 7826, 'Metoclopramide', 'Kidney Diseases', 'Renal function affects the clearance of metoclopramide.  In patients with varying degrees of renal impairment, a reduction in creatinine clearance was correlated with a reduction in plasma clearance, renal clearance, and non-renal clearance, and increase in elimination half-life of metoclopramide.  Therapy with metoclopramide should be administered cautiously in patients with impaired renal function.  A dosage reduction may be appropriate to avoid drug accumulation.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7642, 7827, 'Metoclopramide', 'Kidney Diseases', 'Renal function affects the clearance of metoclopramide.  In patients with varying degrees of renal impairment, a reduction in creatinine clearance was correlated with a reduction in plasma clearance, renal clearance, and non-renal clearance, and increase in elimination half-life of metoclopramide.  Therapy with metoclopramide should be administered cautiously in patients with impaired renal function.  A dosage reduction may be appropriate to avoid drug accumulation.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7643, 7828, 'Metoclopramide', 'Kidney Diseases', 'Renal function affects the clearance of metoclopramide.  In patients with varying degrees of renal impairment, a reduction in creatinine clearance was correlated with a reduction in plasma clearance, renal clearance, and non-renal clearance, and increase in elimination half-life of metoclopramide.  Therapy with metoclopramide should be administered cautiously in patients with impaired renal function.  A dosage reduction may be appropriate to avoid drug accumulation.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7644, 8097, 'Metoclopramide', 'Kidney Diseases', 'Renal function affects the clearance of metoclopramide.  In patients with varying degrees of renal impairment, a reduction in creatinine clearance was correlated with a reduction in plasma clearance, renal clearance, and non-renal clearance, and increase in elimination half-life of metoclopramide.  Therapy with metoclopramide should be administered cautiously in patients with impaired renal function.  A dosage reduction may be appropriate to avoid drug accumulation.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7645, 25000, 'Metoclopramide', 'Kidney Diseases', 'Renal function affects the clearance of metoclopramide.  In patients with varying degrees of renal impairment, a reduction in creatinine clearance was correlated with a reduction in plasma clearance, renal clearance, and non-renal clearance, and increase in elimination half-life of metoclopramide.  Therapy with metoclopramide should be administered cautiously in patients with impaired renal function.  A dosage reduction may be appropriate to avoid drug accumulation.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7646, 25001, 'Metoclopramide', 'Kidney Diseases', 'Renal function affects the clearance of metoclopramide.  In patients with varying degrees of renal impairment, a reduction in creatinine clearance was correlated with a reduction in plasma clearance, renal clearance, and non-renal clearance, and increase in elimination half-life of metoclopramide.  Therapy with metoclopramide should be administered cautiously in patients with impaired renal function.  A dosage reduction may be appropriate to avoid drug accumulation.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7647, 25002, 'Metoclopramide', 'Kidney Diseases', 'Renal function affects the clearance of metoclopramide.  In patients with varying degrees of renal impairment, a reduction in creatinine clearance was correlated with a reduction in plasma clearance, renal clearance, and non-renal clearance, and increase in elimination half-life of metoclopramide.  Therapy with metoclopramide should be administered cautiously in patients with impaired renal function.  A dosage reduction may be appropriate to avoid drug accumulation.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7648, 25257, 'Metoclopramide', 'Kidney Diseases', 'Renal function affects the clearance of metoclopramide.  In patients with varying degrees of renal impairment, a reduction in creatinine clearance was correlated with a reduction in plasma clearance, renal clearance, and non-renal clearance, and increase in elimination half-life of metoclopramide.  Therapy with metoclopramide should be administered cautiously in patients with impaired renal function.  A dosage reduction may be appropriate to avoid drug accumulation.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7649, 25259, 'Metoclopramide', 'Kidney Diseases', 'Renal function affects the clearance of metoclopramide.  In patients with varying degrees of renal impairment, a reduction in creatinine clearance was correlated with a reduction in plasma clearance, renal clearance, and non-renal clearance, and increase in elimination half-life of metoclopramide.  Therapy with metoclopramide should be administered cautiously in patients with impaired renal function.  A dosage reduction may be appropriate to avoid drug accumulation.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7650, 25261, 'Metoclopramide', 'Kidney Diseases', 'Renal function affects the clearance of metoclopramide.  In patients with varying degrees of renal impairment, a reduction in creatinine clearance was correlated with a reduction in plasma clearance, renal clearance, and non-renal clearance, and increase in elimination half-life of metoclopramide.  Therapy with metoclopramide should be administered cautiously in patients with impaired renal function.  A dosage reduction may be appropriate to avoid drug accumulation.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7651, 27683, 'Metoclopramide', 'Kidney Diseases', 'Renal function affects the clearance of metoclopramide.  In patients with varying degrees of renal impairment, a reduction in creatinine clearance was correlated with a reduction in plasma clearance, renal clearance, and non-renal clearance, and increase in elimination half-life of metoclopramide.  Therapy with metoclopramide should be administered cautiously in patients with impaired renal function.  A dosage reduction may be appropriate to avoid drug accumulation.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7652, 29582, 'Metoclopramide', 'Kidney Diseases', 'Renal function affects the clearance of metoclopramide.  In patients with varying degrees of renal impairment, a reduction in creatinine clearance was correlated with a reduction in plasma clearance, renal clearance, and non-renal clearance, and increase in elimination half-life of metoclopramide.  Therapy with metoclopramide should be administered cautiously in patients with impaired renal function.  A dosage reduction may be appropriate to avoid drug accumulation.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7653, 29583, 'Metoclopramide', 'Kidney Diseases', 'Renal function affects the clearance of metoclopramide.  In patients with varying degrees of renal impairment, a reduction in creatinine clearance was correlated with a reduction in plasma clearance, renal clearance, and non-renal clearance, and increase in elimination half-life of metoclopramide.  Therapy with metoclopramide should be administered cautiously in patients with impaired renal function.  A dosage reduction may be appropriate to avoid drug accumulation.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7654, 8083, 'Methylergometrine', 'Cardiotoxicity', 'The amine ergot alkaloids, ergonovine and methylergonovine, can cause serious cardiovascular complications because of their vasospastic effects.  Hypertension (more often with ergonovine) has been most commonly reported, particularly when administered IV undiluted or at an excessive rate or when used in conjunction with regional anesthesia or vasoconstrictors.  Headaches, seizures, cerebrovascular accidents and death have been associated with the hypertensive episodes.  Other, less common adverse effects include acute myocardial infarction, transient chest pains, thrombophlebitis, tachycardia and palpitations.  Therapy with ergot alkaloids should generally be avoided, except under special circumstances, in patients with chronic hypertension, preeclampsia or eclampsia, cardiovascular disease, cerebrovascular disease, or peripheral vascular disease.  Caution is advised when these agents are administered to patients with venoatrial shunts, mitral valve stenosis, or sepsis.  Close monitoring of cardiovascular status is highly recommended during therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7655, 8084, 'Methylergometrine', 'Cardiotoxicity', 'The amine ergot alkaloids, ergonovine and methylergonovine, can cause serious cardiovascular complications because of their vasospastic effects.  Hypertension (more often with ergonovine) has been most commonly reported, particularly when administered IV undiluted or at an excessive rate or when used in conjunction with regional anesthesia or vasoconstrictors.  Headaches, seizures, cerebrovascular accidents and death have been associated with the hypertensive episodes.  Other, less common adverse effects include acute myocardial infarction, transient chest pains, thrombophlebitis, tachycardia and palpitations.  Therapy with ergot alkaloids should generally be avoided, except under special circumstances, in patients with chronic hypertension, preeclampsia or eclampsia, cardiovascular disease, cerebrovascular disease, or peripheral vascular disease.  Caution is advised when these agents are administered to patients with venoatrial shunts, mitral valve stenosis, or sepsis.  Close monitoring of cardiovascular status is highly recommended during therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7656, 31431, 'Methylergometrine', 'Cardiotoxicity', 'The amine ergot alkaloids, ergonovine and methylergonovine, can cause serious cardiovascular complications because of their vasospastic effects.  Hypertension (more often with ergonovine) has been most commonly reported, particularly when administered IV undiluted or at an excessive rate or when used in conjunction with regional anesthesia or vasoconstrictors.  Headaches, seizures, cerebrovascular accidents and death have been associated with the hypertensive episodes.  Other, less common adverse effects include acute myocardial infarction, transient chest pains, thrombophlebitis, tachycardia and palpitations.  Therapy with ergot alkaloids should generally be avoided, except under special circumstances, in patients with chronic hypertension, preeclampsia or eclampsia, cardiovascular disease, cerebrovascular disease, or peripheral vascular disease.  Caution is advised when these agents are administered to patients with venoatrial shunts, mitral valve stenosis, or sepsis.  Close monitoring of cardiovascular status is highly recommended during therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7657, 8083, 'Methylergometrine', 'Hypertension', 'The use of the amine ergot alkaloids, ergonovine and methylergonovine, is considered by some clinicians to be contraindicated in patients with hypertension.  These agents can cause hypertension, particularly when administered IV undiluted or at an excessive rate or when used in conjunction with regional anesthesia or vasoconstrictors.  Headaches, seizures, cerebrovascular accidents and death have been associated with the hypertensive episodes.  Patients with chronic hypertension or preeclampsia may be at increased risk for these complications.  Of the two agents, methylergonovine has less tendency to cause hypertension, although preferably neither agent should be administered to at- risk patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7658, 8084, 'Methylergometrine', 'Hypertension', 'The use of the amine ergot alkaloids, ergonovine and methylergonovine, is considered by some clinicians to be contraindicated in patients with hypertension.  These agents can cause hypertension, particularly when administered IV undiluted or at an excessive rate or when used in conjunction with regional anesthesia or vasoconstrictors.  Headaches, seizures, cerebrovascular accidents and death have been associated with the hypertensive episodes.  Patients with chronic hypertension or preeclampsia may be at increased risk for these complications.  Of the two agents, methylergonovine has less tendency to cause hypertension, although preferably neither agent should be administered to at- risk patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7659, 31431, 'Methylergometrine', 'Hypertension', 'The use of the amine ergot alkaloids, ergonovine and methylergonovine, is considered by some clinicians to be contraindicated in patients with hypertension.  These agents can cause hypertension, particularly when administered IV undiluted or at an excessive rate or when used in conjunction with regional anesthesia or vasoconstrictors.  Headaches, seizures, cerebrovascular accidents and death have been associated with the hypertensive episodes.  Patients with chronic hypertension or preeclampsia may be at increased risk for these complications.  Of the two agents, methylergonovine has less tendency to cause hypertension, although preferably neither agent should be administered to at- risk patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7660, 8083, 'Methylergometrine', 'Liver Diseases', 'The amine ergot alkaloids, ergonovine and methylergonovine, appear to be eliminated by both renal and hepatic routes.  Patients with renal and/or liver disease may be at greater risk for adverse effects from these agents due to decreased drug clearance.  Caution is advised if these agents are used.  Dosage adjustments may be necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7661, 8084, 'Methylergometrine', 'Liver Diseases', 'The amine ergot alkaloids, ergonovine and methylergonovine, appear to be eliminated by both renal and hepatic routes.  Patients with renal and/or liver disease may be at greater risk for adverse effects from these agents due to decreased drug clearance.  Caution is advised if these agents are used.  Dosage adjustments may be necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7662, 31431, 'Methylergometrine', 'Liver Diseases', 'The amine ergot alkaloids, ergonovine and methylergonovine, appear to be eliminated by both renal and hepatic routes.  Patients with renal and/or liver disease may be at greater risk for adverse effects from these agents due to decreased drug clearance.  Caution is advised if these agents are used.  Dosage adjustments may be necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7663, 721, 'Methylnaltrexone', 'Intestinal Obstruction', 'Peripheral opioid receptor antagonists are contraindicated in patients with known or suspected gastrointestinal obstruction, and in patients at increased risk of recurrent obstruction, due to the potential for gastrointestinal perforation.  Cases of gastrointestinal perforation have been reported in patients with opioid-induced constipation and advanced illness with conditions that may be associated with localized or diffuse reduction of structure integrity in the wall of the GI tract such as peptic ulcer, diverticular disease, Crohn''s disease, infiltrative GI tract malignancies or peritoneal metastases.  It is recommended to monitor for the development of severe, persistent, or worsening abdominal pain and to discontinue treatment in patients who develop symptoms.  The overall risk- benefit profile should be carefully evaluated before using these agents in patients with these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7664, 3401, 'Methylnaltrexone', 'Intestinal Obstruction', 'Peripheral opioid receptor antagonists are contraindicated in patients with known or suspected gastrointestinal obstruction, and in patients at increased risk of recurrent obstruction, due to the potential for gastrointestinal perforation.  Cases of gastrointestinal perforation have been reported in patients with opioid-induced constipation and advanced illness with conditions that may be associated with localized or diffuse reduction of structure integrity in the wall of the GI tract such as peptic ulcer, diverticular disease, Crohn''s disease, infiltrative GI tract malignancies or peritoneal metastases.  It is recommended to monitor for the development of severe, persistent, or worsening abdominal pain and to discontinue treatment in patients who develop symptoms.  The overall risk- benefit profile should be carefully evaluated before using these agents in patients with these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7665, 6738, 'Methylnaltrexone', 'Intestinal Obstruction', 'Peripheral opioid receptor antagonists are contraindicated in patients with known or suspected gastrointestinal obstruction, and in patients at increased risk of recurrent obstruction, due to the potential for gastrointestinal perforation.  Cases of gastrointestinal perforation have been reported in patients with opioid-induced constipation and advanced illness with conditions that may be associated with localized or diffuse reduction of structure integrity in the wall of the GI tract such as peptic ulcer, diverticular disease, Crohn''s disease, infiltrative GI tract malignancies or peritoneal metastases.  It is recommended to monitor for the development of severe, persistent, or worsening abdominal pain and to discontinue treatment in patients who develop symptoms.  The overall risk- benefit profile should be carefully evaluated before using these agents in patients with these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7666, 6993, 'Methylnaltrexone', 'Intestinal Obstruction', 'Peripheral opioid receptor antagonists are contraindicated in patients with known or suspected gastrointestinal obstruction, and in patients at increased risk of recurrent obstruction, due to the potential for gastrointestinal perforation.  Cases of gastrointestinal perforation have been reported in patients with opioid-induced constipation and advanced illness with conditions that may be associated with localized or diffuse reduction of structure integrity in the wall of the GI tract such as peptic ulcer, diverticular disease, Crohn''s disease, infiltrative GI tract malignancies or peritoneal metastases.  It is recommended to monitor for the development of severe, persistent, or worsening abdominal pain and to discontinue treatment in patients who develop symptoms.  The overall risk- benefit profile should be carefully evaluated before using these agents in patients with these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7667, 17233, 'Methylnaltrexone', 'Intestinal Obstruction', 'Peripheral opioid receptor antagonists are contraindicated in patients with known or suspected gastrointestinal obstruction, and in patients at increased risk of recurrent obstruction, due to the potential for gastrointestinal perforation.  Cases of gastrointestinal perforation have been reported in patients with opioid-induced constipation and advanced illness with conditions that may be associated with localized or diffuse reduction of structure integrity in the wall of the GI tract such as peptic ulcer, diverticular disease, Crohn''s disease, infiltrative GI tract malignancies or peritoneal metastases.  It is recommended to monitor for the development of severe, persistent, or worsening abdominal pain and to discontinue treatment in patients who develop symptoms.  The overall risk- benefit profile should be carefully evaluated before using these agents in patients with these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7668, 25953, 'Methylnaltrexone', 'Intestinal Obstruction', 'Peripheral opioid receptor antagonists are contraindicated in patients with known or suspected gastrointestinal obstruction, and in patients at increased risk of recurrent obstruction, due to the potential for gastrointestinal perforation.  Cases of gastrointestinal perforation have been reported in patients with opioid-induced constipation and advanced illness with conditions that may be associated with localized or diffuse reduction of structure integrity in the wall of the GI tract such as peptic ulcer, diverticular disease, Crohn''s disease, infiltrative GI tract malignancies or peritoneal metastases.  It is recommended to monitor for the development of severe, persistent, or worsening abdominal pain and to discontinue treatment in patients who develop symptoms.  The overall risk- benefit profile should be carefully evaluated before using these agents in patients with these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7669, 721, 'Methylnaltrexone', 'Hepatic Insufficiency', 'Studies have shown a significant increase in systemic exposure of methylnaltrexone in patients with moderate and severe hepatic impairment, compared to subjects with normal hepatic function.  A dosage reduction is recommended in these patients.  No dose adjustment is needed in patients with mild hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7670, 3401, 'Methylnaltrexone', 'Hepatic Insufficiency', 'Studies have shown a significant increase in systemic exposure of methylnaltrexone in patients with moderate and severe hepatic impairment, compared to subjects with normal hepatic function.  A dosage reduction is recommended in these patients.  No dose adjustment is needed in patients with mild hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7671, 6738, 'Methylnaltrexone', 'Hepatic Insufficiency', 'Studies have shown a significant increase in systemic exposure of methylnaltrexone in patients with moderate and severe hepatic impairment, compared to subjects with normal hepatic function.  A dosage reduction is recommended in these patients.  No dose adjustment is needed in patients with mild hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7672, 6993, 'Methylnaltrexone', 'Hepatic Insufficiency', 'Studies have shown a significant increase in systemic exposure of methylnaltrexone in patients with moderate and severe hepatic impairment, compared to subjects with normal hepatic function.  A dosage reduction is recommended in these patients.  No dose adjustment is needed in patients with mild hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7673, 17233, 'Methylnaltrexone', 'Hepatic Insufficiency', 'Studies have shown a significant increase in systemic exposure of methylnaltrexone in patients with moderate and severe hepatic impairment, compared to subjects with normal hepatic function.  A dosage reduction is recommended in these patients.  No dose adjustment is needed in patients with mild hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7674, 25953, 'Methylnaltrexone', 'Hepatic Insufficiency', 'Studies have shown a significant increase in systemic exposure of methylnaltrexone in patients with moderate and severe hepatic impairment, compared to subjects with normal hepatic function.  A dosage reduction is recommended in these patients.  No dose adjustment is needed in patients with mild hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7675, 721, 'Methylnaltrexone', 'Kidney Diseases', 'Patients with moderate, severe and end-stage renal disease have shown to exhibit markedly higher systemic exposure to peripheral opioid receptor antagonists such as methylnaltrexone and naloxegol, compared to subjects with normal renal function.  A dose reduction is recommended for these patients.  No dosage adjustment is needed in patients with mild renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7676, 3401, 'Methylnaltrexone', 'Kidney Diseases', 'Patients with moderate, severe and end-stage renal disease have shown to exhibit markedly higher systemic exposure to peripheral opioid receptor antagonists such as methylnaltrexone and naloxegol, compared to subjects with normal renal function.  A dose reduction is recommended for these patients.  No dosage adjustment is needed in patients with mild renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7677, 6738, 'Methylnaltrexone', 'Kidney Diseases', 'Patients with moderate, severe and end-stage renal disease have shown to exhibit markedly higher systemic exposure to peripheral opioid receptor antagonists such as methylnaltrexone and naloxegol, compared to subjects with normal renal function.  A dose reduction is recommended for these patients.  No dosage adjustment is needed in patients with mild renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7678, 6993, 'Methylnaltrexone', 'Kidney Diseases', 'Patients with moderate, severe and end-stage renal disease have shown to exhibit markedly higher systemic exposure to peripheral opioid receptor antagonists such as methylnaltrexone and naloxegol, compared to subjects with normal renal function.  A dose reduction is recommended for these patients.  No dosage adjustment is needed in patients with mild renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7679, 17233, 'Methylnaltrexone', 'Kidney Diseases', 'Patients with moderate, severe and end-stage renal disease have shown to exhibit markedly higher systemic exposure to peripheral opioid receptor antagonists such as methylnaltrexone and naloxegol, compared to subjects with normal renal function.  A dose reduction is recommended for these patients.  No dosage adjustment is needed in patients with mild renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7680, 25953, 'Methylnaltrexone', 'Kidney Diseases', 'Patients with moderate, severe and end-stage renal disease have shown to exhibit markedly higher systemic exposure to peripheral opioid receptor antagonists such as methylnaltrexone and naloxegol, compared to subjects with normal renal function.  A dose reduction is recommended for these patients.  No dosage adjustment is needed in patients with mild renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7681, 17239, 'Metolazone', 'Anuria', 'The use of thiazide diuretics is contraindicated in patients with anuria.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7682, 18087, 'Metolazone', 'Anuria', 'The use of thiazide diuretics is contraindicated in patients with anuria.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7683, 22666, 'Metolazone', 'Anuria', 'The use of thiazide diuretics is contraindicated in patients with anuria.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7684, 26084, 'Metolazone', 'Anuria', 'The use of thiazide diuretics is contraindicated in patients with anuria.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7685, 17239, 'Metolazone', 'Water-Electrolyte Imbalance', 'The use of thiazide diuretics is commonly associated with loss of electrolytes, most significantly potassium but also sodium, chloride, bicarbonate, and magnesium.  The loss of other electrolytes such as phosphate, bromide and iodide is usually slight.  Potassium and magnesium depletion may lead to cardiac arrhythmias and cardiac arrest.  Other electrolyte-related complications include metabolic alkalosis and hyponatremia, which are rarely life-threatening.  Therapy with thiazide diuretics should be administered cautiously in patients with or predisposed to fluid and electrolyte depletion, including patients with primary or secondary aldosteronism (may have low potassium levels); those with severe or prolonged diarrhea or vomiting; and those with poor nutritional status.  Fluid and electrolyte abnormalities should be corrected prior to initiating therapy, and blood pressure as well as serum electrolyte concentrations monitored periodically and maintained at normal ranges during therapy.  Patients should be advised to immediately report signs and symptoms of fluid or electrolyte imbalance, including dry mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, arrhythmia, or gastrointestinal disturbances such as nausea and vomiting.  Digitalized patients and patients with a history of ventricular arrhythmias should be monitored carefully, since development of hypokalemia may be particularly dangerous in these patients.  The risk of hypokalemia may be minimized by slow diuresis, a lower thiazide dosage, potassium supplementation, or combined use with a potassium-sparing diuretic.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7686, 18087, 'Metolazone', 'Water-Electrolyte Imbalance', 'The use of thiazide diuretics is commonly associated with loss of electrolytes, most significantly potassium but also sodium, chloride, bicarbonate, and magnesium.  The loss of other electrolytes such as phosphate, bromide and iodide is usually slight.  Potassium and magnesium depletion may lead to cardiac arrhythmias and cardiac arrest.  Other electrolyte-related complications include metabolic alkalosis and hyponatremia, which are rarely life-threatening.  Therapy with thiazide diuretics should be administered cautiously in patients with or predisposed to fluid and electrolyte depletion, including patients with primary or secondary aldosteronism (may have low potassium levels); those with severe or prolonged diarrhea or vomiting; and those with poor nutritional status.  Fluid and electrolyte abnormalities should be corrected prior to initiating therapy, and blood pressure as well as serum electrolyte concentrations monitored periodically and maintained at normal ranges during therapy.  Patients should be advised to immediately report signs and symptoms of fluid or electrolyte imbalance, including dry mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, arrhythmia, or gastrointestinal disturbances such as nausea and vomiting.  Digitalized patients and patients with a history of ventricular arrhythmias should be monitored carefully, since development of hypokalemia may be particularly dangerous in these patients.  The risk of hypokalemia may be minimized by slow diuresis, a lower thiazide dosage, potassium supplementation, or combined use with a potassium-sparing diuretic.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7687, 22666, 'Metolazone', 'Water-Electrolyte Imbalance', 'The use of thiazide diuretics is commonly associated with loss of electrolytes, most significantly potassium but also sodium, chloride, bicarbonate, and magnesium.  The loss of other electrolytes such as phosphate, bromide and iodide is usually slight.  Potassium and magnesium depletion may lead to cardiac arrhythmias and cardiac arrest.  Other electrolyte-related complications include metabolic alkalosis and hyponatremia, which are rarely life-threatening.  Therapy with thiazide diuretics should be administered cautiously in patients with or predisposed to fluid and electrolyte depletion, including patients with primary or secondary aldosteronism (may have low potassium levels); those with severe or prolonged diarrhea or vomiting; and those with poor nutritional status.  Fluid and electrolyte abnormalities should be corrected prior to initiating therapy, and blood pressure as well as serum electrolyte concentrations monitored periodically and maintained at normal ranges during therapy.  Patients should be advised to immediately report signs and symptoms of fluid or electrolyte imbalance, including dry mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, arrhythmia, or gastrointestinal disturbances such as nausea and vomiting.  Digitalized patients and patients with a history of ventricular arrhythmias should be monitored carefully, since development of hypokalemia may be particularly dangerous in these patients.  The risk of hypokalemia may be minimized by slow diuresis, a lower thiazide dosage, potassium supplementation, or combined use with a potassium-sparing diuretic.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7688, 26084, 'Metolazone', 'Water-Electrolyte Imbalance', 'The use of thiazide diuretics is commonly associated with loss of electrolytes, most significantly potassium but also sodium, chloride, bicarbonate, and magnesium.  The loss of other electrolytes such as phosphate, bromide and iodide is usually slight.  Potassium and magnesium depletion may lead to cardiac arrhythmias and cardiac arrest.  Other electrolyte-related complications include metabolic alkalosis and hyponatremia, which are rarely life-threatening.  Therapy with thiazide diuretics should be administered cautiously in patients with or predisposed to fluid and electrolyte depletion, including patients with primary or secondary aldosteronism (may have low potassium levels); those with severe or prolonged diarrhea or vomiting; and those with poor nutritional status.  Fluid and electrolyte abnormalities should be corrected prior to initiating therapy, and blood pressure as well as serum electrolyte concentrations monitored periodically and maintained at normal ranges during therapy.  Patients should be advised to immediately report signs and symptoms of fluid or electrolyte imbalance, including dry mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, arrhythmia, or gastrointestinal disturbances such as nausea and vomiting.  Digitalized patients and patients with a history of ventricular arrhythmias should be monitored carefully, since development of hypokalemia may be particularly dangerous in these patients.  The risk of hypokalemia may be minimized by slow diuresis, a lower thiazide dosage, potassium supplementation, or combined use with a potassium-sparing diuretic.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7689, 17239, 'Metolazone', 'Liver Diseases', 'Patients with severe liver disease or cirrhosis are very susceptible to thiazide-induced hypokalemic hypochloremic alkalosis.  Blood ammonia concentrations may be further increased in patients with previously elevated concentrations.  Hepatic encephalopathy and death have occurred secondary to the electrolyte alterations accompanying diuretic use.  Therapy with thiazide diuretics should be administered cautiously in patients with impaired hepatic function or progressive liver disease, and discontinued promptly if signs of impending hepatic coma appear (e.g., tremors, confusion, and increased jaundice).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7690, 18087, 'Metolazone', 'Liver Diseases', 'Patients with severe liver disease or cirrhosis are very susceptible to thiazide-induced hypokalemic hypochloremic alkalosis.  Blood ammonia concentrations may be further increased in patients with previously elevated concentrations.  Hepatic encephalopathy and death have occurred secondary to the electrolyte alterations accompanying diuretic use.  Therapy with thiazide diuretics should be administered cautiously in patients with impaired hepatic function or progressive liver disease, and discontinued promptly if signs of impending hepatic coma appear (e.g., tremors, confusion, and increased jaundice).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7691, 22666, 'Metolazone', 'Liver Diseases', 'Patients with severe liver disease or cirrhosis are very susceptible to thiazide-induced hypokalemic hypochloremic alkalosis.  Blood ammonia concentrations may be further increased in patients with previously elevated concentrations.  Hepatic encephalopathy and death have occurred secondary to the electrolyte alterations accompanying diuretic use.  Therapy with thiazide diuretics should be administered cautiously in patients with impaired hepatic function or progressive liver disease, and discontinued promptly if signs of impending hepatic coma appear (e.g., tremors, confusion, and increased jaundice).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7692, 26084, 'Metolazone', 'Liver Diseases', 'Patients with severe liver disease or cirrhosis are very susceptible to thiazide-induced hypokalemic hypochloremic alkalosis.  Blood ammonia concentrations may be further increased in patients with previously elevated concentrations.  Hepatic encephalopathy and death have occurred secondary to the electrolyte alterations accompanying diuretic use.  Therapy with thiazide diuretics should be administered cautiously in patients with impaired hepatic function or progressive liver disease, and discontinued promptly if signs of impending hepatic coma appear (e.g., tremors, confusion, and increased jaundice).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7693, 17239, 'Metolazone', 'Lupus Erythematosus, Systemic', 'The use of thiazide diuretics has been reported to possibly exacerbate or activate systemic lupus erythematosus.  Reported cases have generally been associated with chlorothiazide and hydrochlorothiazide.  Therapy with thiazide diuretics should be administered cautiously in patients with a history or risk of SLE.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7694, 18087, 'Metolazone', 'Lupus Erythematosus, Systemic', 'The use of thiazide diuretics has been reported to possibly exacerbate or activate systemic lupus erythematosus.  Reported cases have generally been associated with chlorothiazide and hydrochlorothiazide.  Therapy with thiazide diuretics should be administered cautiously in patients with a history or risk of SLE.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7695, 22666, 'Metolazone', 'Lupus Erythematosus, Systemic', 'The use of thiazide diuretics has been reported to possibly exacerbate or activate systemic lupus erythematosus.  Reported cases have generally been associated with chlorothiazide and hydrochlorothiazide.  Therapy with thiazide diuretics should be administered cautiously in patients with a history or risk of SLE.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7696, 26084, 'Metolazone', 'Lupus Erythematosus, Systemic', 'The use of thiazide diuretics has been reported to possibly exacerbate or activate systemic lupus erythematosus.  Reported cases have generally been associated with chlorothiazide and hydrochlorothiazide.  Therapy with thiazide diuretics should be administered cautiously in patients with a history or risk of SLE.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7697, 17239, 'Metolazone', 'Kidney Failure, Chronic', 'Thiazide diuretics may be ineffective when the glomerular filtration rate is low (GFR < 25 mL/min) because they are not expected to be filtered into the renal tubule, their site of action.  In addition, thiazide diuretics decrease the GFR and may precipitate azotemia in renal disease.  Cumulative effects may also develop because most of these drugs are excreted unchanged in the urine by glomerular filtration and active tubular secretion.  Therapy with thiazide diuretics should be administered cautiously at reduced dosages in patients with renal impairment.  If renal function becomes progressively worse, as indicated by rising BUN or serum creatinine levels, an interruption or discontinuation of thiazide therapy should be considered.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7698, 18087, 'Metolazone', 'Kidney Failure, Chronic', 'Thiazide diuretics may be ineffective when the glomerular filtration rate is low (GFR < 25 mL/min) because they are not expected to be filtered into the renal tubule, their site of action.  In addition, thiazide diuretics decrease the GFR and may precipitate azotemia in renal disease.  Cumulative effects may also develop because most of these drugs are excreted unchanged in the urine by glomerular filtration and active tubular secretion.  Therapy with thiazide diuretics should be administered cautiously at reduced dosages in patients with renal impairment.  If renal function becomes progressively worse, as indicated by rising BUN or serum creatinine levels, an interruption or discontinuation of thiazide therapy should be considered.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7699, 22666, 'Metolazone', 'Kidney Failure, Chronic', 'Thiazide diuretics may be ineffective when the glomerular filtration rate is low (GFR < 25 mL/min) because they are not expected to be filtered into the renal tubule, their site of action.  In addition, thiazide diuretics decrease the GFR and may precipitate azotemia in renal disease.  Cumulative effects may also develop because most of these drugs are excreted unchanged in the urine by glomerular filtration and active tubular secretion.  Therapy with thiazide diuretics should be administered cautiously at reduced dosages in patients with renal impairment.  If renal function becomes progressively worse, as indicated by rising BUN or serum creatinine levels, an interruption or discontinuation of thiazide therapy should be considered.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7700, 26084, 'Metolazone', 'Kidney Failure, Chronic', 'Thiazide diuretics may be ineffective when the glomerular filtration rate is low (GFR < 25 mL/min) because they are not expected to be filtered into the renal tubule, their site of action.  In addition, thiazide diuretics decrease the GFR and may precipitate azotemia in renal disease.  Cumulative effects may also develop because most of these drugs are excreted unchanged in the urine by glomerular filtration and active tubular secretion.  Therapy with thiazide diuretics should be administered cautiously at reduced dosages in patients with renal impairment.  If renal function becomes progressively worse, as indicated by rising BUN or serum creatinine levels, an interruption or discontinuation of thiazide therapy should be considered.', '3', '', 'DDInter', 0);
